| Lennox-Gastaut Syndrome
Fintepla vs Sympazan
Side-by-side clinical, coverage, and cost comparison for lennox-gastaut syndrome.Deep comparison between: Fintepla vs Sympazan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSympazan has a higher rate of injection site reactions vs Fintepla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sympazan but not Fintepla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Fintepla
Sympazan
At A Glance
Oral
Twice daily
5-HT2 receptor agonist
Oral film
Twice daily
Benzodiazepine
Indications
- Infantile Severe Myoclonic Epilepsy
- Lennox-Gastaut syndrome
- Lennox-Gastaut syndrome
Dosing
Infantile Severe Myoclonic Epilepsy, Lennox-Gastaut syndrome Initial 0.1 mg/kg twice daily orally, titrated weekly; maintenance up to 0.35 mg/kg twice daily (max 26 mg/day); with concomitant stiripentol plus clobazam, maximum 0.2 mg/kg twice daily (max 17 mg/day).
Lennox-Gastaut syndrome Weight <=30 kg: initiate at 5 mg/day, titrate up to 20 mg/day; weight >30 kg: initiate at 10 mg/day, titrate up to 40 mg/day; doses above 5 mg/day given in two divided doses twice daily; do not escalate more rapidly than weekly.
Contraindications
- Hypersensitivity to fenfluramine or any of the excipients in FINTEPLA
- Concomitant use, or within 14 days of administration, of monoamine oxidase inhibitors
- History of hypersensitivity to clobazam or any of its ingredients, including serious dermatological reactions
Adverse Reactions
Most common (>=10%) Decreased appetite, somnolence/sedation/lethargy, diarrhea, fatigue/malaise/asthenia, abnormal echocardiogram, ataxia/balance disorder/gait disturbance, blood pressure increased, drooling/salivary hypersecretion, pyrexia, upper respiratory tract infection, vomiting, weight decreased
Serious Valvular heart disease, pulmonary arterial hypertension, decreased appetite and decreased weight, somnolence/sedation/lethargy, suicidal behavior and ideation, serotonin syndrome, increase in blood pressure, glaucoma, status epilepticus
Postmarketing Aggression
Most common (>=5%) Somnolence or sedation, pyrexia, upper respiratory tract infection, lethargy, aggression, drooling, irritability, insomnia, ataxia, vomiting, constipation, cough, fatigue, decreased appetite, increased appetite
Serious Respiratory depression (with opioids), abuse and addiction, dependence and withdrawal reactions, serious dermatological reactions, drug reaction with eosinophilia and systemic symptoms (DRESS), suicidal behavior and ideation, neonatal sedation and withdrawal syndrome
Postmarketing Anemia, eosinophilia, leukopenia, thrombocytopenia, diplopia, blurred vision, abdominal distention, hypothermia, hepatic enzyme increased, muscle spasms, agitation, anxiety, depression, delirium, hallucination, urinary retention, aspiration, respiratory depression, rash, urticaria, angioedema
Pharmacology
Fenfluramine and its metabolite norfenfluramine exhibit agonist activity at serotonin 5-HT2 receptors; the precise mechanism by which this produces antiseizure effects in Dravet syndrome and Lennox-Gastaut syndrome is unknown, though 5-HT2B receptor agonism is associated with valvular heart disease and pulmonary arterial hypertension risk.
Clobazam is a 1,5-benzodiazepine whose mechanism is thought to involve potentiation of GABAergic neurotransmission through binding at the benzodiazepine site of the GABA-A receptor; it is extensively metabolized to N-desmethylclobazam, an active metabolite with approximately 1/5 the activity of the parent compound.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Fintepla
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (9/12)
Sympazan
- Covered on 5 commercial plans
- PA (8/12) · Step Therapy (3/12) · Qty limit (11/12)
UnitedHealthcare
Fintepla
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Sympazan
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Fintepla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Sympazan
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25
ONWARD Copay Assistance Program: FinteplaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Sympazan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FinteplaView full Fintepla profile
SympazanView full Sympazan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.